- A meta-analysis ties dual BRAF+MEK inhibition to an excess risk for cardiovascular adverse events (CVAEs) vs BRAF inhibitors alone in patients with melanoma.
Why this matters
- A recent meta-analysis showed survival benefit with dual BRAF/MEK inhibition, but risks and benefit should be carefully weighed.
- Combination vs monotherapy was associated with increased risks for:
- Pulmonary embolism (2.2% vs 0.4%; risk ratio [RR], 4.36; P=.02).
- Decreased left ventricular ejection fraction (LVEF: 8.1% vs 2.0%; RR, 3.72; P<.001>
- Arterial hypertension (19.5% vs 14.0%; RR, 1.49; P=.005).
- Decreased LVEF (2.1% vs 0.7%; RR, 2.79; P=.005).
- Arterial hypertension (8.0% vs 5.1%; RR, 1.54, P=.005).
- 5 randomized clinical trials involving 2317 patients with melanoma were included in the meta-analysis.
- Funding: none disclosed.
- Treatment regimens were different in the included studies.